2062株大肠杆菌ESBL测定及耐药分析  

The ESBL screening and antibiotical susceptibility of 2026 E.coli strains

作　　者：姜森[1] 张正[1] 杨朵[1] 王贺[1] 

机构地区：[1]北京大学人民医院检验科,北京100044

出　　处：《中国实验诊断学》2008年第9期1134-1136,共3页Chinese Journal of Laboratory Diagnosis

摘　　要：目的探讨我院2001-2006年ESBL+大肠杆菌的阳性率,流行趋势和耐药分析,为临床合理选用抗生素提供依据。方法收集我院六年来大肠杆菌共2062株,双纸片协同测试法检出ESBL+大肠杆菌834株,并用VITEK-TWO自动微生物鉴定系统进行药敏试验。结果ESBL+大肠杆菌检出率平均为40%,药敏试验,对亚胺培南的耐药率低于2%,对哌拉西林/他唑巴坦(特治星)耐药率平均为10.5%,对头孢哌酮/舒巴坦(舒普深)的耐药率为5.9%,对阿米卡星的耐药率平均为17%,对呋喃妥因的耐药率平均为17.6%,对其他药物的耐药率均较高。结论治疗ESBL+大肠杆菌感染的首选药物是泰能,其次是特治星和舒普深,除此还可选用阿米卡星和呋喃妥因。Objective To onvestage the ESBL-producing rate of E. coli of year 2001 to 2006 in the people＇ s hospital. And the antibiotical susceptibility of ESBL positive strains have been tested. Methods We tested 2062 E. coli strains for screening ESBL-producing strains used double dise synergy test. There are 834 strains ESBL positive. The antibiotical susceptibility test is taken by vitek 2 system. Results ESBL-producing rate is about 40% in clinic E. coli strains. The resistance to Imipenem is lower titan 2%, and the resistance to Piperacillin/tazobactam, Cefoperazone/Sulbact, Amikacin and Nitroufantoin is 10.5 %, 5.9 %, 17 %, 17.6 % respectively. Conclusion It should better to use Imipenem to kill ESBL positive E. coli , and it also can use Piperacillin/Tazobactam, Cefoperazone/Sulbact and Amikacin for infection caused by ESBL（ ＋ ） E. coli.

关 键 词：ESBL+大肠杆菌 耐药分析 

分 类 号：R446.5[医药卫生—诊断学]